| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8445524 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895756 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
| US8609863 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
| US8791270 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
|
US8609863 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(2 years from now) | |
|
US8791270 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(2 years from now) | |
|
US8895756 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(2 years from now) | |
| US8883836 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(5 years from now) | |
| US9533955 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(5 years from now) | |
| US8669279 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(5 years from now) | |
| US8344006 | CEPHALON | Liquid formulations of bendamustine |
Sep, 2029
(5 years from now) | |
|
US9533955 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(5 years from now) | |
|
US8883836 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(5 years from now) | |
|
US8669279 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(5 years from now) | |
|
US8445524 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(5 years from now) | |
|
US8344006 (Pediatric) | CEPHALON | Liquid formulations of bendamustine |
Mar, 2030
(6 years from now) | |
| US8436190 | CEPHALON | Bendamustine pharmaceutical compositions |
Oct, 2030
(7 years from now) | |
|
US8436190 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Apr, 2031
(7 years from now) | |
Treanda is owned by Cephalon.
Treanda contains Bendamustine Hydrochloride.
Treanda has a total of 18 drug patents out of which 0 drug patents have expired.
Treanda was authorised for market use on 20 March, 2008.
Treanda is available in powder;iv (infusion), solution;iv (infusion) dosage forms.
Treanda can be used as for use in the treatment of patients with indolent b-cell non-hodgkin lymphoma; for use in the treatment of patients with chronic lymphocytic leukemia (cll), for use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma, for use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl).
The generics of Treanda are possible to be released after 26 April, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE* (ODE*) | Dec 7, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 20 March, 2008
Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell...
Dosage: POWDER;IV (INFUSION); SOLUTION;IV (INFUSION)
TREANDA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic